The short version: in March 2002 FDA issued a consumer advisory warning that kava-containing dietary supplements may be associated with a rare but severe risk of liver injury, and that advisory is still the reason kava carries a flag in FDA's ingredient directory today. The case record behind it is real but small, roughly two decades old, and heavily confounded by extraction solvent, cultivar, plant part and co-medication. Kava is still lawfully sold as a dietary supplement in the United States, and the industry's answer has been a standardised caution label rather than a ban.
What follows is what the record contains, what it does not, and what we would require of a kava brand before stocking it. Botanical Blends is a distributor and retailer — we do not manufacture, formulate or blend anything — so our leverage is entirely in what we agree to carry. This reflects where things stood on 30 July 2026.
Quick answer
| Question | Where the record stands |
|---|---|
| Did FDA warn about kava and the liver? | Yes — a consumer advisory issued in March 2002. It is an advisory, not a prohibition. |
| Is there a federally mandated kava liver warning? | No. Anyone who tells you otherwise is wrong. The warning in common use is a trade-association standard. |
| How large is the case record? | Small — on the order of a hundred reported cases worldwide across two decades, against very large exposure — and heavily confounded. |
| Are there drug interactions? | Yes, and they are the more practically important issue for most people. Kavalactones affect several CYP450 enzymes and P-glycoprotein. |
| Is kava a Prop 65 substance? | Not on the list version current when this post was published. IARC classifies kava extract in Group 2B, which is the kind of profile that can lead to listing. |
What happened in 2002
Between 1998 and 2002 a cluster of hepatotoxicity case reports emerged in Europe, primarily Germany and Switzerland, associated with kava-containing products. Some were serious: cases of hepatitis, cirrhosis and liver failure, including transplants and deaths. German regulators withdrew kava's marketing authorisation in 2002 — a decision that was subsequently litigated and reversed, then partially reinstated with restrictions, a back-and-forth that ran for more than a decade and is itself a signal that the evidence was never regarded as settled.
FDA's response was a consumer advisory in March 2002, warning that kava-containing dietary supplements may be associated with severe liver injury and advising people with liver disease or taking medicines that affect the liver to consult a physician before use. FDA did not remove kava from the market, and has not since. In its current Dietary Supplement Ingredient Directory, kava appears solely as an ingredient that is the subject of a safety communication. That is a meaningful placement: it is not among the categories FDA uses for ingredients it considers unlawful in supplements. The full regulatory picture is in our post on what kava is and where it stands legally.
How strong is the signal, honestly?
Weaker than the headlines and stronger than the industry usually admits. Several things make the case series hard to interpret.
Extraction solvent. A large share of the European cases involved acetone or ethanol extracts. The traditional Pacific preparation is aqueous, and populations with centuries of heavy traditional consumption did not produce a comparable hepatotoxicity signal. FDA's own toxicology review has acknowledged the better tolerability record of the traditional aqueous preparation. This is the single most-cited confounder.
Plant part. Some implicated material appears to have included stem peelings and aerial parts rather than root and rhizome alone. Aerial parts carry compounds — pipermethystine among them — that are largely absent from properly sourced root and that have shown toxicity to liver cells in laboratory studies.
Cultivar. Non-noble kava, including tudei types, has a different kavalactone profile and higher levels of flavokavain B, a chalcone that has drawn attention in the hepatotoxicity discussion. We cover the distinction and how to verify it in noble versus tudei kava.
Co-exposure. Many case reports involved concurrent alcohol use, concurrent medication, or pre-existing liver conditions. Published re-analyses concluded that causality was probable or certain in only a minority of the reported cases.
None of that makes the signal disappear. Idiosyncratic drug-induced liver injury is, by definition, rare, unpredictable and not dose-dependent in the ordinary way — which means a small case series is exactly what a real idiosyncratic signal looks like. The responsible reading is that the risk appears to be rare, that several product-quality variables plausibly drive most of it, and that those variables are controllable by whoever writes the purchase order.
The AHPA warning, and why it is the standard of care
There is no federally required liver warning for kava. What exists instead is a trade requirement adopted by the American Herbal Products Association, and it has become the de facto standard of care for the US supplement channel. In substance it advises that FDA has warned of a potential risk of rare but severe liver injury associated with kava-containing dietary supplements; tells the reader to ask a healthcare professional before use if they have or have had liver problems, frequently use alcoholic beverages, or take any medication; tells them to stop use and see a doctor if symptoms that may signal liver problems appear; and states that the product is not for use by people under 18, by pregnant or breastfeeding women, or with alcoholic beverages, and that excessive use or use with products causing drowsiness may impair the ability to operate a vehicle or machinery.
We treat that text as a hard onboarding condition. Any kava product we stocked would have to arrive from the brand with that text already on the label, and we would repeat it on the product page. Two reasons. The first is that it is good information and people deserve it. The second is less romantic: in a product-liability posture, the question is not whether a warning was legally mandated but whether the seller met the standard of care that the industry itself had already published. Omitting a warning your own trade association requires is not a defensible position.
One caveat on the numbers that float around alongside it. Sources conflict on whether AHPA states a numeric kavalactone cap and on the revision date of the requirement. Rather than print a figure we cannot confirm, our buying spec uses the limits applied by Australia's medicines regulator — no more than 250 mg of kavalactones per day and no more than 125 mg per dosage unit — which are stricter than the figure usually attributed to AHPA and therefore safe in both directions.
Drug interactions, which matter more day to day
For most people this is the more practically relevant section. Kavalactones inhibit several cytochrome P450 enzymes — CYP1A2, CYP2C19 and CYP3A4 are the ones most consistently reported — and interact with P-glycoprotein, a transporter that governs how many drugs are absorbed and cleared. That combination means kava has the potential to change blood levels of a wide range of medications, in either direction, including some where the therapeutic window is narrow.
The practical upshot is simple and we will not dress it up: if you take prescription medication of any kind, this is a conversation for your pharmacist or physician, not for a product page. The same goes for anyone with a history of liver problems, anyone who drinks regularly, and anyone who is pregnant or breastfeeding.
Alcohol deserves its own line. Combining kava with alcohol is contraindicated in every serious guidance document we have read, and the AHPA text says so directly.
Driving is the last item. Published research has associated driving in the hours after kava use with a substantially increased crash risk, and impaired-driving arrests involving kava have been reported in the United States. A driving and machinery caution belongs on the label, and we require one.
IARC, Prop 65 and the thing we are watching
The International Agency for Research on Cancer classified kava extract as Group 2B — possibly carcinogenic to humans. The classification rests substantially on positive liver tumour findings in rodent bioassay work run by the US National Toxicology Program. Group 2B is a large and heterogeneous category reflecting strength of evidence rather than size of risk, but it is a real finding and we are not going to pretend otherwise.
Kava is not on the California Proposition 65 list as of the most recent list revision we checked before publishing this post on 30 July 2026. A Group 2B classification supported by a positive rodent bioassay is close to the archetypal profile for a future listing, and a listing would give sellers roughly twelve months before a warning obligation attached. We re-check the state list quarterly for that reason.
The one combination we will never carry
Kava-plus-kratom products exist. We will not stock one under any circumstances, and the reason is not only that it would contradict a kratom-free catalogue. Published poison-centre surveillance has found that a substantial share of kava-related reports also involved kratom. A combination product stacks an unresolved hepatic question on top of a compound class that is the subject of an active federal scheduling action, and there is no version of that we would defend. Our position on kratom-derived compounds generally is set out in how cat's claw differs from kratom and 7-OH.
What we will not claim, in either direction
We are not going to tell you kava is safe. Safety is not a property a plant has; it is a function of dose, duration, preparation, product quality and the person taking it, and no honest retailer can certify it.
We are also not going to tell you kava is dangerous in a way the evidence does not support. The record describes a rare signal, concentrated in a period and a product profile that responsible sourcing can largely avoid, in a plant that remains lawfully sold as a dietary supplement in the United States.
What we will do is publish the certificates the brands supply, require the warning, hold to a documented buying ceiling on dose, insist that cultivar and plant part are named, and tell you where the evidence runs out. That is the whole offer. How to work through any certificate is in how to read a certificate of analysis, the lab reports themselves live on the COA page, and the standing terms are on the disclaimer page.
Frequently Asked Questions
Did FDA ban kava?
No. FDA issued a consumer advisory in March 2002 and has not removed kava from the market. It appears in FDA's ingredient directory only as the subject of a safety communication, not in any of the categories used for ingredients FDA considers unlawful in supplements.
Is the liver warning on kava labels required by law?
Not federally. The widely used text is a trade requirement from the American Herbal Products Association. We treat it as mandatory anyway, because it is the published industry standard of care.
Why do people say water-extracted kava is different?
Because a large share of the European case reports involved acetone or ethanol extracts, while the traditional Pacific preparation is aqueous and did not generate a comparable signal. Extraction solvent is one of the few variables a buyer can actually control, which is why we ask for it on the label.
Should I take kava if I am on medication?
Ask your pharmacist or physician first. Kavalactones affect CYP1A2, CYP2C19 and CYP3A4 and interact with P-glycoprotein, which means they can alter levels of a broad range of drugs. This is not something a product page can answer for you.
Does the 2026 DEA scheduling action affect kava?
No. Every compound named in the July 2026 Federal Register notices — FR Doc 2026-13580 and FR Doc 2026-13581 — is a kratom-derived or kratom-related alkaloid. Kava is a different plant and is not named in either.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Legality depends on the specific formulation and applicable state law — check the rules where you live. Nothing here is legal advice.